The personal utility outcomes of the IMPACT-AD BC study have now been peer-reviewed and published in one of the leading journals in the field dementia care:
Patel K, Yang D, Feldman HH, Hsiung GYR, Nygaard H, Best JR, Dwosh E, Robillard JM, DeMarco ML. Personal value of Alzheimer’s disease biomarker testing and result disclosure from the patient and care partner perspective. Alzheimer's & Dementia 2024;10(2):e12463.
Prior to the IMPACT-AD BC study, our understanding of patient and caregiver perspectives with Alzheimer's disease biomarker testing originated primarily from disclosure of amyloid imaging results in controlled research settings. We found limited information on the experiences of patients and caregivers with AD cerebrospinal fluid biomarker testing and disclosure in clinical practice, and impacts on decision-making and planning.
The IMPACT-AD BC study was undertaken to help overcome these shortcomings.This observational study of patients who underwent Alzheimer's disease biomarker testing as part of usual medical care, and their care partner, revealed diagnostic clarity was the major driver for testing, and both groups used the biomarker results to their benefit in making wellness and lifestyle changes, and in preparing for the future.
For additional details please see the peer-reviewed scientific article:
Comments